Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer

Inclusion Criteria

• •Age \>18
• •WHO performance status 0-2
• •Life expectancy ≥ 3 months
• •Patients receiving androgen-suppressive therapy in the form of chirurgical castration by orchiectomy or pulpectomy,or medical by LHRH agonist or antagonist with or without anti-androgen or all treatment blocking non gonadic testosterone fraction
• •Resulting to testosteronemia \<0,5 ng/ml
• •Histologically confirmed adenocarcinomia of prostate cancer and documented hormone independant metastatic disease - defined by: objective progression with at least one measurable lesion and/or evaluable lesion according to RECIST criteria and /or a rise in PSA level ("rising PSA")
• •Total bilirubin ≤ upper limit of normal (ULN).
• •AST and ALT ≤ 1.5 times ULN. Alkaline phosphatase ≤ 2.5 times ULN.
• •Serum creatinine \< 140 µmol/L or creatinine clearance \> 60 mL/ min.
• •Neutrophil count \> 2.109 L-1.
• •Platelet count ≥ 100,000/mm3.
• •Hemoglobin ≥ 10 g/dL
• •Not previous chemotherapy, except Estracyt
• •No liver, kidney or heart failure link to treatment
• •No malabsorption syndrome or disease significantly affecting gastrointestinal function
• •Prior radiotherapies are permetted withing four weeks of the first study treatment and must be \< 25 % of the bone marrow, and all adverse events must be resolved
• •Prior surgery are permitted.